Creo Medical Share Discussion Threads

[parob] 04/8/2023 12:15

Top sliced a few HVO and added here. Back to my original holding amount now. Decent update.

[dr biotech] 04/8/2023 11:25

I don't think broker targets of 4-5x the current price are particularly helpful. A £500m valuation will need profits of £40m pa at some point. Whilst I think that is possible, its not going to happen within the next 2-3 years which is a reasonable investment timeline.

Would be far better to have a target of say 60p with upgrades if/when sales momentum really starts to take off. I am not expecting the real picture to become clear for another 18months.

I used to work in scientific instrument sales - I know this is a different area but the product profiles aren't dissimilar. It takes 3-5 years to get any really significant sales and I am expecting the same here. However if sales really start to grow, I don't see this as staying independent.

FWIW this is 2% of my total. I have 35 individual holdings, largest is KITW at about 8%. Smallest (mostly duff investments that have fallen) are around 0.3%, so its an average size holding for me.

[master investor] 04/8/2023 11:00

Edison raise price target to 150p

[master investor] 04/8/2023 10:59

Edison coverage"Creo Medical - Entering phase of accelerating growth inflectionFY22 was a key inflection period for Creo with significant traction in the adoption of Speedboat Inject (its flagship electrosurgical device) and its proprietary CROMA technology platform, reflected in major robotic deals with Intuitive Surgical and CMR Surgical. Total revenue growth (8% y-o-y to £27.2m) was in line with consensus (£27m) and was primarily driven by Creo's core technology business. Operating losses rose to £30.8m, affected by increased personnel and R&D expenses, although management expects a sharp reduction from FY23 following cost-optimisation measures implemented in H222. We expect further expansion of the Speedboat Inject user base (with an emphasis on training enrolment) to be the strategic priority in FY23. With the recent fund-raise of £33.7m (gross) in Q123, we estimate the company is funded to operational profitability in H126. Incorporating the improved cash balance post the reporting period, our valuation increases to £528m (150p/share) from £493m."Cenkos coverage"Investment thesis – We believe Creo Medical is at a significant inflection point in its development, with an increasing number of core Creo device users undertaking procedures on a regular basis, two Kamaptive licensing agreements announced and regional expansion of its consumables business underway. With the near-term cash concerns resolved following the recent equity raise, we expect the shares to perform strongly. We maintain our Buy recommendation."

[barbelsue] 03/8/2023 20:50

pacsitd

no. bit closer to the 2 house brokers than a bloke in the pub. I think its a strength

[master investor] 03/8/2023 15:10

I'm with you. This is my largest holding now.

[master investor] 03/8/2023 15:08

Surely they would have Been flushed out by now. I know several big buyers since the placing.

[pacsltd] 03/8/2023 13:06

You know? A bloke down the pub is it :)

[barbelsue] 03/8/2023 12:54

I know there is at least one big seller from the Placing

[someuwin] 03/8/2023 11:49

Happy to hold a big chunk here. The direction of travel has to be continuing upwards from here as the tech gets rolled out across the world. Plus the added unknowns of more devices being added and new procedures benefitting from their products. And the almost inevitable takeover at some point in the future.

[master investor] 03/8/2023 11:23

The volume is very low. Im not convinced we have a big seller tbh.

[barbelsue] 03/8/2023 11:08

Great update but we need the / these sellers to be cleared. Placing shares at 20p are going to be sold for a decent profit whatever the potential upside.

[someuwin] 03/8/2023 08:21

Cenkos summary today...

"Investment thesis – We believe Creo Medical is at a significant inflection point in its development, with an increasing number of core Creo device users undertaking procedures on a regular basis, two Kamaptive licensing agreements announced and regional expansion of its consumables business underway. With the near-term cash concerns resolved following the recent equity raise, we expect the shares to perform strongly. We maintain our Buy recommendation."

[hatfullofsky] 03/8/2023 07:59

Nice update, let's see what the market makes of it.

[hatfullofsky] 28/7/2023 12:31

and in France but not registered on their feeds or website, weird.



They are also expanding in Germany

[someuwin] 28/7/2023 10:17

Creo Medical @CreoMedical ·57m

Singapore secures SSD service!

Dr Yim Heng Boon from Mount Elizabeth Novena Medical Center, #Singapore has become the first physician in the country to offer and #SSD service, making advanced energy endoscopic treatment in the #GI tract available to patients in the region👏

[parob] 28/7/2023 09:40

Might be a good call MI. GOOD luck to you :)

[master investor] 28/7/2023 09:39

Golden Cross incoming. Text book cup and handle and chart oversold. I've just added another 50k shares this morning.

[parob] 28/7/2023 09:34

Double top at 37p and dropping down below recent support. It could come back though so holding for now. I switched some funds to STX and that seems to have been the right move.

[master investor] 28/7/2023 09:29

What don't you like about the chart?

[parob] 28/7/2023 08:54

OK I won't mention STX again although I do think it has better prospects in the short/medium term, but I wasn't talking CREO down, I still have a holding here but I don't like the look of the chart, and I may take more profits if it falls anymore, and keep some in for the longer term. I bought at average 24p so don't want to see profits dwindle away.

[pacsltd] 27/7/2023 16:02

@Parob would you mind not talking down CREO and skip over to the STX chat in

[parob] 27/7/2023 15:05

Don't like the look of this chart. FFS.Sold a few and added more to STX whilst it's dipping.